Cumberland Pharmaceuticals' antibiotic Vibativ (telavancin) injection has gained approval from China’s National Medical ...

Gene therapy stocks are transforming healthcare with revolutionary treatments. Therefore, as this sector continues to evolve, ...

China NMPA accepts for review GSK’s Nucala NDA to treat patients with chronic obstructive pulmonary disease: London, UK Friday, February 21, 2025, 09:00 Hrs [IST] GSK plc announ ...

Specialty pharmaceutical companies Cumberland Pharmaceuticals Inc. and SciClone Pharmaceuticals (Holdings) Limited ("SciClone Pharmaceuticals" or "SciClone") today announced the NMPA (National Medical ...

Pfizer's strong Q4 2024 results showcase growth in cancer drugs and Vyndaqel sales. Learn why PFE stock is a top pick for ...

Hong Kong Department of Health accepts IASO Bio’s NDA for equecabtagene autoleucel to treat r/r multiple myeloma: Shanghai, Nanjing Monday, February 17, 2025, 17:00 Hrs [IST] IA ...

"Net sales increased during the fourth quarter by 41.5 percent to SEK 64.2 million, compared with the corresponding quarter of 2023. The growth and strong performance are a result of robust developmen ...

Between 2018 and 2024, China has launched 188 domestically developed innovative drugs – nearly double the number from the ...

If approved, the med would be the only targeted ... approval from China's National Medical Products Administration (NMPA) to treat adults with multiple myeloma who've received at least one prior ...